Home > Insider Trading > Filing (0001062993-21-007983)

Filing Details

Accession Number:: 0001062993-21-007983
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-08-26 19:29:53
Reporting Period:: 2021-08-24

Accepted Time:: 2021-08-26 19:29:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1808805	Nautilus Biotechnology Inc.	NAUT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1381752	S Matthew Mcilwain	C/O Madrona Venture Group 999 Third Avenue, 34Th Floor Seattle WA 98104		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-08-24	13,568	$7.68	335,673	No	4	P	Direct
Common Stock	Acquisiton	2021-08-25	11,693	$7.74	347,366	No	4	P	Direct
Common Stock	Acquisiton	2021-08-26	11,709	$7.71	359,075	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	5,798,394	Indirect	By Madrona Venture Fund VI, LP
Common Stock	222,376	Indirect	By Madrona Venture Fund VI-A, LP

Footnotes

The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.56 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.69 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.67 to $7.75, inclusive. The reporting person undertakes to provide to Nautilus Biotechnology, Inc., any security holder of Nautilus Biotechnology, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Shares held by Madrona Venture Fund VI, LP ("Madrona Fund VI"). Madrona Investment Partners VI, L.P. ("Madrona Partners VI") is the general partner of Madrona Fund VI, and Madrona VI General Partner, LLC ("Madrona VI LLC") is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
Shares held by Madrona Venture Fund VI-A, LP ("Madrona Fund VI-A"). Madrona Partners VI is the general partner of Madrona Fund VI-A, and Madrona VI LLC is the general partner of Madrona Partners VI. The reporting person, is a managing member of Madrona VI LLC. The reporting person disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of benefical ownership of all of the reported shares for purposes of Section 16 or for any other purpose.